Intracellular Th Company Overview
About Intracellular Th
Intracellular Therapies (NASDAQ:ITCI) is a biopharmaceutical company focused on the development and commercialization of therapies for patients with neuropsychiatric and neurologic disorders, including schizophrenia and depression. Intracellular Therapies aims to leverage its expertise in the science of intracellular signaling to bring forward novel, efficacious treatments that improve patients' lives. Key projects include the continued development and marketing of CAPLYTA® (lumateperone) for schizophrenia and bipolar depression, along with an expanding pipeline of innovative compounds in various stages of clinical development. The company's objectives center around advancing research and development in central nervous system disorders, with a commitment to uncovering breakthrough therapies that can address unmet medical needs in mental health and neurological conditions.
Snapshot
Operations
Produtos e/ou serviços de Intracellular Th
- Development of groundbreaking therapies targeting neuropsychiatric and neurodegenerative diseases, leveraging intracellular signaling mechanisms.
- Innovative research on small molecule inhibitors to correct protein misfolding, addressing Huntington's and Alzheimer's diseases.
- Advanced drug delivery technologies enhancing the bioavailability and targeting efficiency of CNS therapeutics.
- Cutting-edge diagnostic tools for early identification and tracking of CNS disorder progression.
- Collaboration on clinical trials aimed at evaluating the efficacy and safety of novel therapeutic candidates for schizophrenia.
- Partnership programs with academic and industry leaders to accelerate the development of targeted treatments for CNS disorders.
equipe executiva do Intracellular Th
- Dr. Sharon Mates Ph.D.Co-Founder, Chairman & CEO
- Mr. Michael I. Halstead J.D.President
- Mr. Sanjeev NarulaExecutive VP, CFO & Treasurer
- Dr. Suresh K. Durgam M.D.Executive VP & Chief Medical Officer
- Mr. Mark NeumannEVP & Chief Commercial Officer
- Dr. Robert E. Davis Ph.D.Senior VP & Chief Scientific Officer
- Mr. Juan Fernando Sanchez M.D.Vice President of Corporate Communications & Investor Relations
- Ms. Karen Patruno Sheehy Esq.Senior VP & Chief Compliance Officer
- John P. CondonSenior VP, General Counsel & Secretary
- Dr. Michael Olchaskey Pharm.D.Senior VP & Head of Regulatory Affairs